GNRX
VanEck Vectors Generic Drugs ETF
GNRX
GNRX
Delisted
GNRX was delisted on the 4th of April, 2019.
2 hedge funds and large institutions have $1.33M invested in VanEck Vectors Generic Drugs ETF in 2016 Q1 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
2
Holders Change
+2
Holders Change %
–
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
UBS Group
Zurich,
Switzerland
|
+$1.32M |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$7K |
Top Sellers
No sellers this quarter
| Name | Holding | Trade Value |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $1.32M | +$1.32M | +55,000 | New |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $7K | +$7K | +291 | New |
|